The Parliamentary Committee on Security Services has unanimously approved the importation of Methylphenidate, a key medication used in the treatment of children with Attention-Deficit/Hyperactivity Disorder (ADHD).
Methylphenidate is widely regarded as a first-line treatment for ADHD. However, access to the medication in the Maldives has faced significant challenges due to its classification under the list of prohibited substances in the country’s Narcotics Act.
After reviewing the matter, the committee decided to support removing the medication from the restricted list, citing the importance of ensuring treatment access for children with ADHD. Following the committee’s approval, the matter is expected to proceed for a final decision by Parliament.
Parents of children with ADHD and healthcare professionals have long advocated for the medication to be made available in the Maldives, arguing that access to treatment is essential for improving quality of life and supporting children’s development.
The decision is expected to mark a significant step forward in expanding treatment options for ADHD in the country.